Implementation of Suicide Risk Models in Health Systems
Launched by KAISER PERMANENTE · Sep 27, 2023
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This trial is testing whether using a computer-based suicide risk model in behavioral health clinics can help prevent suicide attempts. Clinics are randomly assigned to either continue with their usual care or to start using the risk model as part of a new care pathway, and, in a crossover design, clinics switch between approaches in three waves. The main goal is to see if implementing the model reduces suicide attempts within 90 days after a behavioral health visit. Researchers will also look at how often risk is identified, whether a formal risk assessment is completed, whether safety steps (like a safety plan or counseling about lethal means) are used, and whether patients get quick follow-up with behavioral health services within 14 days, following about 18 months of study follow-up.
Who can join: adults 18 and older who have at least one behavioral health clinic visit at participating sites. There are no extra exclusion rules beyond this. The study is being done across three large health systems—Henry Ford Health, HealthPartners, and Kaiser Permanente—and aims to include a broad, real-world patient group. It’s not a drug or device trial. Results aren’t available yet (enrollment is ongoing with an estimated 394,000 participants), but the trial will help show whether adding a risk-model-based approach in real clinics improves prevention efforts and outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 18+ years old
- • 1+ visit to a behavioral health clinic at participating sites
- Exclusion Criteria:
- • None
About Kaiser Permanente
Kaiser Permanente is a leading integrated health care organization that combines a health plan with a network of hospitals and physicians to provide comprehensive medical services. With a strong commitment to advancing medical research and improving patient care, Kaiser Permanente sponsors clinical trials across various therapeutic areas. The organization emphasizes innovative approaches to health care, leveraging its extensive data and resources to support evidence-based treatments and enhance patient outcomes. Through its rigorous research initiatives, Kaiser Permanente aims to contribute to the advancement of medical knowledge and the development of new therapies that benefit diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Detroit, Michigan, United States
Portland, Oregon, United States
Bloomington, Minnesota, United States
Patients applied
Trial Officials
Bobbi Jo Yarborough, PsyD
Principal Investigator
Kaiser Permanente
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported